
Follistatin-344 is a potent natural antagonist of myostatin, the body's primary brake on skeletal muscle growth. It has demonstrated remarkable lean mass effects in every animal model tested, from mice to nonhuman primates, and is the only follistatin isoform with human clinical trial data (gene therapy for Becker muscular dystrophy). Not approved for human use. This is not medical advice.
Quick Reference: Standard Protocol
| Parameter |
Standard Protocol |
| Dose |
50 mcg |
| Route |
Intramuscular injection (IM) |
| Timing |
30 minutes pre-workout |
| Frequency |
Training days only |
| Cycle |
8 weeks on, 8 weeks off |
| Vial size |
1 mg |
| Reconstitution |
2 mL bacteriostatic water → 500 mcg/mL |
| Draw amount |
10 units on insulin syringe |
| Storage |
Lyophilized: -20°C long-term / 2-8°C short-term. Reconstituted: 2-8°C, use within 14-21 days |
Standard protocol: 50 mcg IM injection 30 minutes before training. Training days only -- no injection on rest days. 8 weeks on, 8 weeks off.
For the full Follistatin-344 peptide profile, see our follistatin peptide page. For the complete mechanism, see our follistatin benefits guide.
Cycling: 8 Weeks On, 8 Weeks Off
Inject 50 mcg intramuscularly 30 minutes before training, on training days only. Rest days are off days. This targets myostatin inhibition around resistance training sessions when it matters most.
The 8-week off period allows the body's myostatin/follistatin axis to re-equilibrate and provides a safety window to monitor for emerging side effects.
IM injection sites: Deltoid (most common for small-volume IM), vastus lateralis (outer thigh), or gluteus medius (upper outer glute).
Routes of Administration
Intramuscular injection (standard): IM is the primary route for follistatin-344. The training-day-only timing targets the muscle-building window directly. Use a 29-31 gauge insulin syringe for the small volume.
Note on pharmacokinetics: Community peptide doses are extrapolated from gene-therapy studies that used viral vector delivery (sustained local expression over weeks). Direct injection of recombinant follistatin has a much shorter half-life (estimated hours), so the pharmacokinetics are fundamentally different. This is the major caveat underlying all community dosing.
Reconstitution Quick Reference

| Vial Size |
BAC Water |
Concentration |
50 mcg Dose |
| 1 mg |
2 mL |
500 mcg/mL |
10 units |
Math: 1,000 mcg / 2 mL = 500 mcg/mL. For 50 mcg: 50 / 500 = 0.1 mL = 10 units. One vial lasts 20 doses.
Follistatin-344 is a fragile protein -- swirl very gently, never shake. May take 2-5 minutes to dissolve completely. Solution should be clear. Refrigerate immediately. Do not freeze reconstituted solution. Use within 14-21 days. Discard if cloudy or contains particles.
For step-by-step instructions, see the Reconstitution Calculator.
Where These Numbers Come From
Follistatin-344 has unusually robust preclinical and early clinical evidence:
Mouse studies (Haidet et al., 2008): Single AAV-delivered follistatin-344 produced sustained muscle mass increases of over 20% in both normal and dystrophic mice, lasting 2+ years. FS344 outperformed all other myostatin inhibitors tested.
Nonhuman primates (Kota et al., 2009): AAV1-delivered FS344 increased muscle size and strength in macaques with no adverse immune response and no effect on reproductive hormones.
Human clinical trial (Mendell et al., 2015): Phase 1/2a AAV1.CMV.FS344 gene therapy in Becker muscular dystrophy patients improved 6-minute walk test distance with no serious adverse events and no reproductive hormone changes.
Porcine model (Guo et al., 2017): Transgenic pigs expressing human follistatin-344 showed significantly increased skeletal muscle mass via myofiber hypertrophy.
Stacking Protocols
| Stack |
Components |
Purpose |
| GH + Myostatin |
FS-344 50 mcg + CJC-1295/Ipamorelin |
Myostatin inhibition + GH/IGF-1 |
| Growth Factor |
FS-344 50 mcg + IGF-1 LR3 |
Myostatin block + direct IGF-1 receptor activation |
| Connective Tissue Support |
FS-344 50 mcg + BPC-157 + TB-500 |
Muscle growth + tendon/ligament adaptation |
Stacking tips: No clinical data validates any combinations. Start with FS-344 alone for at least one cycle before adding partners. BPC-157 and TB-500 are popular protective additions to help tendons/ligaments adapt to increased muscular loading.
Side Effects & Safety
- Injection site reactions -- redness, swelling, itching (most common)
- Transient fatigue -- some users report mild fatigue in first 2-3 days
- Joint stiffness -- occasionally reported, typically mild
- Elevated appetite -- consistent with increased metabolic demand
- Reproductive concerns (theoretical) -- follistatin is involved in FSH regulation, though FS344 has lower FSH-suppressing activity than FS288. No reproductive hormone changes observed in the Mendell clinical trial
- Tendon/ligament adaptation lag -- rapid muscle growth without proportional connective tissue strengthening may increase injury risk
- Avoid if: active cancer, pregnancy/breastfeeding, autoimmune conditions, under 18
Frequently Asked Questions
What is the typical Follistatin-344 dose?
50 mcg intramuscular injection, 30 minutes before training, on training days only. Use a 1 mg vial with 2 mL BAC water -- 50 mcg = 10 units.
How long should a Follistatin-344 cycle last?
8 weeks on, 8 weeks off. Training-day-only dosing.
Does Follistatin-344 need to be refrigerated?
Yes. Lyophilized: -20°C long-term, 2-8°C short-term. Reconstituted: 2-8°C, use within 14-21 days.
Is Follistatin-344 the same as Follistatin-315?
FS-344 is the gene/mRNA (344 amino acids). After processing, the mature protein is FS315 (315 amino acids). Same isoform, different stages.
Is Follistatin-344 approved for human use?
No. It is a research chemical only. The only human data comes from a gene therapy trial (AAV delivery), not injectable peptide use.
References
| Citation |
Topic |
PMID |
| Lee & McPherron, PNAS (2001) |
Myostatin regulation by follistatin |
11459935 |
| Haidet et al., PNAS (2008) |
Long-term muscle enhancement via FS344 gene delivery |
18334646 |
| Kota et al., Sci Transl Med (2009) |
FS344 gene delivery in nonhuman primates |
20368179 |
| Mendell et al., Mol Ther (2015) |
Phase 1/2a FS344 gene therapy in Becker MD |
25322757 |
| Guo et al., Transgenic Res (2017) |
Human FS344 expression in pigs |
27787698 |
| Amthor et al., Dev Biol (2004) |
Follistatin-myostatin binding mechanism |
15136138 |
For educational and research purposes only. This is not medical advice. Follistatin-344 is not approved for human use by any regulatory agency.